Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels

NCT06496243 · tracked via the Priya Life Science USA tracker

Sponsor

NewAmsterdam Pharma

Phase

Phase 2

Started

2024-12-02

Last updated

2026-04-09

Condition(s) studied

Dyslipidemias

Investigational drug(s) / intervention(s)

obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks

obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks: 10 mg obicetrapib for 8 weeks followed by 10 mg obicetrapib/ 140 mg evolocumab (every 2 weeks) combination for 8 weeks

Study summary

The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab

Patients will:

Have baseline Lp(a) tested at randomization Take 10mg/dL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 Take 10 mg/dL obicetrapib daily/evolocumab 140 every other week for 8 weeks and have Lp(a) retested at Week 16

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: * Lp(a): \>=50 mg/dL (\>=125 nmol/L) for cohort 1 (FILLED) and Lp(a) \>= 20 mg/dL (\>= 50 nmol/L) to \<50 mg/dL (\< 125 nmol/L) for cohort 2 * LDL-C \>70 mg/dL * TG \< 400mg/dL (\<4.52 mmol/L) Exclusion Criteria: * HbA1c\>=10 or FPG \>=270 mg/dL * CV events within 3 months of screen

Primary outcome measure(s)

To evaluate the effect of evolocumab in combination with obicetrapib on lipoprotein (a) (Lp[a]). — 16 weeks from baseline; 8 weeks on combination therapy
Lp(a) change on combination therapy

Trial sites (1)

Facility	City	Region	Status
UPenn	Philadelphia	Pennsylvania	Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06496243 on ClinicalTrials.gov ↗ ← All trials in the USA